Fieldfisher advises Cryolife on the acquisition of JOTEC Group
CryoLife acquires German-based JOTEC Group for a purchase price of $225 million.
Düsseldorf, 17 October 2017 – Fieldfisher (Germany) LLP advised CryoLife, Inc., a NYSE-listed leading medical device and tissue processing company focussed on cardiac and vascular surgery, on its acquisition of German JOTEC Group.
CryoLife acquires German-based JOTEC Group for a purchase price of $225 million, subject to certain adjustments consisting of 75 percent in cash and 25 percent in CryoLife common stock issued to JOTEC Group's shareholders.
About CryoLife: CryoLife is a leader in the development, manufacturing and distribution of implantable living tissues used in cardiac and vascular surgical procedures. Headquartered in suburban Atlanta, Georgia, CryoLife markets its medical devices in more than 80 countries worldwide.
About JOTEC Group: JOTEC Group develops, produces and markets a comprehensive product portfolio for surgical and endovascular stent grafting systems and is headquartered in Hechingen, Germany.
Advisors Fieldfisher: Dr. Susanne Rückert (lead partner/corporate Germany), David Kent (Corporate UK), Marcus Kamp (Employment), Philipp Stricharz (Real Estate), Dr. Stefanie Greifeneder (Commercial), Dr. Cord Wilhöft (Life Sciences), Benjamin Grzimek (IP), Dr. Sascha Dethof (Competition).
Inhouse CryoLife: Jean Holloway, Andrew Crouse, Karen Dabbs
US Advisors Cryolife: Vinson & Elkins (Paul Tobias, Andy Smetana)